Is PYREXIA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed PYREXIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 191 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported PYREXIA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and PYREXIA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause PYREXIA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes PYREXIA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if PYREXIA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing PYREXIA: 191
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where PYREXIA is a reported side effect: 5.7375%

FDA reports of any drug causing PYREXIA : 111364
Average percentage for all medicated patients where PYREXIA is reported as a complication: 0.6980%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
ANGINA PECTORIS ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with PYREXIA:

HUMIRA (7595 patients)
ASPIRIN (5953 patients)
REMICADE (5234 patients)
METHOTREXATE (5232 patients)
PREDNISONE (4893 patients)
PREDNISOLONE (4557 patients)
HEPARIN SODIUM INJECTION (4324 patients)
ENBREL (3597 patients)
ACETAMINOPHEN (3597 patients)
ZOMETA (3558 patients)
AVONEX (3381 patients)
LASIX (3343 patients)
OMEPRAZOLE (3235 patients)
FOSAMAX (3183 patients)
FOLIC ACID (3123 patients)
CYCLOPHOSPHAMIDE (2893 patients)
DEXAMETHASONE (2712 patients)
NEXIUM (2584 patients)
LIPITOR (2506 patients)
ALLOPURINOL (2390 patients)
VIOXX (2386 patients)
FUROSEMIDE (2225 patients)
TYSABRI (2085 patients)
CYCLOSPORINE (2084 patients)
PREDNISONE TAB (2069 patients)
LAMICTAL (2036 patients)
REVLIMID (2011 patients)
SYNTHROID (2005 patients)
EXJADE (1957 patients)
LISINOPRIL (1926 patients)
NEURONTIN (1875 patients)
COUMADIN (1867 patients)
DECADRON (1858 patients)
FLUOROURACIL (1855 patients)
SOLIRIS (1852 patients)
NEORAL (1851 patients)
IBUPROFEN (1821 patients)
OXYCONTIN (1817 patients)
PROTONIX (1801 patients)
NORVASC (1795 patients)
NEXAVAR (1792 patients)
AREDIA (1777 patients)
ZOFRAN (1744 patients)
LEVOTHYROXINE SODIUM (1724 patients)
CISPLATIN (1721 patients)
SIMVASTATIN (1710 patients)
CLOZARIL (1707 patients)
ATENOLOL (1688 patients)
SEROQUEL (1685 patients)
PRILOSEC (1664 patients)
XANAX (1646 patients)
POTASSIUM CHLORIDE (1630 patients)
VANCOMYCIN (1628 patients)
GLEEVEC (1612 patients)
TEGRETOL (1579 patients)
ACYCLOVIR (1579 patients)
ALBUTEROL (1571 patients)
RIBAVIRIN (1549 patients)
BACTRIM (1547 patients)
ZOLOFT (1539 patients)
AMBIEN (1527 patients)
ATIVAN (1510 patients)
CARBOPLATIN (1500 patients)
LORAZEPAM (1490 patients)
LANSOPRAZOLE (1456 patients)
PEGASYS (1452 patients)
PAXIL (1441 patients)
FLUCONAZOLE (1434 patients)
VITAMIN D (1421 patients)
PLAVIX (1418 patients)
VELCADE (1406 patients)
GABAPENTIN (1399 patients)
HYDROCHLOROTHIAZIDE (1378 patients)
MYCOPHENOLATE MOFETIL (1360 patients)
LYRICA (1337 patients)
LEVAQUIN (1331 patients)
CIPROFLOXACIN (1317 patients)
MORPHINE (1301 patients)
FAMOTIDINE (1292 patients)
DIOVAN (1290 patients)
CYTARABINE (1286 patients)
VICODIN (1276 patients)
CLONAZEPAM (1268 patients)
DIGOXIN (1263 patients)
REBIF (1245 patients)
CELEBREX (1242 patients)
OXYCODONE HCL (1232 patients)
FORTEO (1223 patients)
VINCRISTINE (1218 patients)
CALCIUM (1213 patients)
DOXORUBICIN HCL (1177 patients)
ZOCOR (1167 patients)
TAXOTERE (1156 patients)
NEUPOGEN (1156 patients)
WARFARIN SODIUM (1148 patients)
AMLODIPINE (1146 patients)
METFORMIN HCL (1138 patients)
PREVACID (1132 patients)
AMOXICILLIN (1126 patients)
BETASERON (1118 patients)
CLOZAPINE (1106 patients)
PERCOCET (1100 patients)
ETOPOSIDE (1099 patients)
TOPROL-XL (1093 patients)
IMMUCYST (1091 patients)
VOLTAREN (1078 patients)
MULTI-VITAMINS (1072 patients)
METHYLPREDNISOLONE (1069 patients)
ZANTAC (1065 patients)
AUGMENTIN '125' (1051 patients)
LEXAPRO (1047 patients)
BENADRYL (1040 patients)
RITUXIMAB (1037 patients)
TACROLIMUS (1037 patients)
CYMBALTA (1037 patients)
TYLENOL (CAPLET) (1033 patients)
DIAZEPAM (1027 patients)
SINGULAIR (1018 patients)
ACCUTANE (1010 patients)
LANTUS (1006 patients)
SOLU-MEDROL (1005 patients)
AVASTIN (1000 patients)
FENTANYL (1000 patients)
CRESTOR (986 patients)
TRAMADOL HCL (977 patients)
SYNAGIS (969 patients)
METOPROLOL TARTRATE (953 patients)
LEVOFLOXACIN (948 patients)
ZYPREXA (943 patients)
TAXOL (932 patients)
INSULIN (922 patients)
BEVACIZUMAB (921 patients)
AZATHIOPRINE (915 patients)
PACLITAXEL (915 patients)
PEG-INTRON (912 patients)
DIFLUCAN (912 patients)
TYLENOL (910 patients)
LOVENOX (906 patients)
XELODA (900 patients)
HEPARIN (899 patients)
CLARITHROMYCIN (897 patients)
AFINITOR (893 patients)
ARANESP (890 patients)
THYMOGLOBULIN (888 patients)
DURAGESIC-100 (887 patients)
RECLAST (886 patients)
NEULASTA (885 patients)
EFFEXOR (883 patients)
MAGNESIUM OXIDE (879 patients)
PREDONINE (878 patients)
OXALIPLATIN (878 patients)
COMPAZINE (870 patients)
FLAGYL (867 patients)
ALPRAZOLAM (860 patients)
LOXONIN (852 patients)
ZYRTEC (852 patients)
MULTI-VITAMIN (842 patients)
RISPERDAL (840 patients)
ADVAIR DISKUS 100/50 (840 patients)
DEPAKENE (836 patients)
DOCETAXEL (836 patients)
VALTREX (820 patients)
CALCIUM CARBONATE (817 patients)
PROGRAF (812 patients)
PANTOPRAZOLE (810 patients)
CELLCEPT (798 patients)
ZITHROMAX (798 patients)
THALIDOMIDE (791 patients)
KLONOPIN (788 patients)
BACLOFEN (782 patients)
KETEK (782 patients)
LAMIVUDINE (775 patients)
GEMZAR (775 patients)
DIANEAL (770 patients)
PROZAC (765 patients)
ROCEPHIN (760 patients)
COPEGUS (759 patients)
KALETRA (756 patients)
LORTAB (753 patients)
SPIRIVA (751 patients)
WELLBUTRIN (750 patients)
CELEXA (748 patients)
COLACE (748 patients)
RANITIDINE (748 patients)
MORPHINE SULFATE (745 patients)
MUCOSTA (742 patients)
ALDACTONE (742 patients)
CAPECITABINE (739 patients)
CERTICAN (735 patients)
BYETTA (730 patients)
REBETOL (726 patients)
VITAMIN B-12 (726 patients)
DILAUDID (724 patients)
ENALAPRIL MALEATE (716 patients)
SPIRONOLACTONE (715 patients)
AMITRIPTYLINE HCL (707 patients)
PARACETAMOL (706 patients)
RAMIPRIL (691 patients)
REGLAN (690 patients)
NYSTATIN (688 patients)
ONDANSETRON (682 patients)
PREMARIN (681 patients)
METRONIDAZOLE (670 patients)
TASIGNA (670 patients)
LEUCOVORIN CALCIUM (670 patients)
AVELOX (669 patients)
PEPCID (665 patients)
CARBAMAZEPINE (664 patients)
NITROGLYCERIN (664 patients)
ALLEGRA (661 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about PYREXIA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.